Novartis Sets Eyes on Chinese Vaccine Market
Taskin Ahmed
Abstract
Swiss drug maker, Novartis is to pay US$125 M to acquire 85% of the Chinese vaccine manufacturer, Zhejiang Tianyuan, in its bid to build a strong presence in China.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.